Company Performance Metrics
Exosla develops pre-clinical extracellular vesicle-based immunotherapies at the intersection of regenerative medicine and immunology. The company focuses on high-performing exosomes derived from monoclonal mesenchymal stem or stromal cell lines. Its platforms use engineered and immortalized monoclonal lines to create a continuous and uniform cell
source for therapeutic extracellular vesicles. By standardizing cell banks, Exosla addresses batch-to-batch variability that is common with primary tissue-derived products and supports GMP-ready development. Its research pipeline targets immune-related conditions, including neuroinflammation, ophthalmology indications, and complex autoimmune diseases. Exosla aims to translate vesicle biology into non-proliferative, cell-free treatment candidates that are positioned as alternatives to traditional stem cell therapies.
